News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
497,661 Results
Type
Article (10694)
Company Profile (148)
Press Release (486817)
Multimedia
Podcasts (15)
Webinars (6)
Section
Business (170364)
Career Advice (360)
Deals (26238)
Drug Delivery (13)
Drug Development (54756)
Employer Resources (16)
FDA (10191)
Job Trends (9037)
News (244295)
Policy (18701)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (1)
Academia (751)
Accelerated approval (26)
ADA (18)
Adcomms (3)
Allergies (98)
Alliances (34097)
ALS (132)
Alzheimer's disease (1179)
Antibody-drug conjugate (ADC) (286)
Approvals (10814)
Artificial intelligence (367)
ASCO (164)
Autoimmune disease (214)
Automation (29)
Bankruptcy (268)
Best Places to Work (7345)
BIO (36)
BIOSECURE Act (1)
Biosimilars (148)
BioSpace Insights (30)
Biotechnology (94)
Bladder cancer (138)
Brain cancer (30)
Breast cancer (507)
Cancer (3703)
Cardiovascular disease (221)
Career advice (293)
Career pathing (5)
CAR-T (176)
CDC (2)
Celiac Disease (1)
Cell therapy (491)
Cervical cancer (34)
Clinical research (49419)
Collaboration (1346)
Commercialization (3)
Compensation (1446)
Complete response letters (38)
COVID-19 (797)
CRISPR (63)
C-suite (794)
Cystic fibrosis (85)
Data (5851)
Decentralized trials (1)
Denatured (8)
Depression (144)
Dermatology (63)
Diabetes (344)
Diagnostics (4222)
Digital health (43)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (172)
Drug pricing (21)
Drug shortages (3)
Duchenne muscular dystrophy (172)
Earnings (74331)
Editorial (7)
Employer branding (2)
Employer resources (16)
Events (89159)
Executive appointments (747)
FDA (12904)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (19)
Frontotemporal dementia (24)
Funding (996)
Gene editing (125)
Generative AI (10)
Gene therapy (335)
GLP-1 (328)
Government (1056)
Grass and pollen (2)
Guidances (296)
Healthcare (9704)
Hematology (106)
HIV (53)
Huntington's disease (29)
IgA nephropathy (68)
Immunology and inflammation (121)
Immuno-oncology (59)
Indications (162)
Infectious disease (986)
Inflammatory bowel disease (147)
Inflation Reduction Act (5)
Influenza (84)
Intellectual property (257)
Interviews (49)
IPO (12534)
IRA (5)
Job creations (2072)
Job search strategy (275)
JPM (18)
Kidney cancer (16)
Labor market (8)
Layoffs (107)
Leadership (3)
Legal (5448)
Licensing (7)
Liver cancer (45)
Longevity (15)
Lung cancer (520)
Lymphoma (257)
Machine learning (29)
Management (4)
Manufacturing (557)
Marketing (8)
MASH (120)
Medical device (8831)
Medtech (8977)
Mergers & acquisitions (14765)
Metabolic disorders (731)
mRNA (66)
Multiple sclerosis (133)
NASH (4)
Neurodegenerative disease (286)
Neuropsychiatric disorders (68)
Neuroscience (2391)
Neurotech (1)
NextGen: Class of 2026 (3318)
Non-profit (1047)
Now hiring (8)
Obesity (242)
Opinion (28)
Ovarian cancer (161)
Pain (192)
Pancreatic cancer (200)
Parkinson's disease (263)
Partnered (12)
Patents (484)
Patient recruitment (515)
Peanut (31)
People (42596)
Pharmaceutical (31)
Pharmacy benefit managers (10)
Phase 1 (15750)
Phase 2 (21930)
Phase 3 (15172)
Pipeline (7462)
Policy (30)
Postmarket research (1676)
Preclinical (6744)
Press Release (34)
Prostate cancer (192)
Psychedelics (18)
Radiopharmaceuticals (190)
Rare diseases (607)
Real estate (3154)
Recruiting (6)
Regulatory (15356)
Reports (20)
Research institute (811)
Resumes & cover letters (51)
Rett syndrome (41)
RNA editing (6)
RSV (49)
Schizophrenia (154)
Series A (167)
Series B (134)
Service/supplier (5)
Sickle cell disease (62)
Special edition (7)
Spinal muscular atrophy (109)
Sponsored (6)
Startups (2118)
Stomach cancer (3)
Supply chain (52)
Tariffs (3)
The Weekly (7)
Vaccines (330)
Venture capital (32)
Weight loss (83)
Women's health (82)
Worklife (1)
Date
Today (71)
Last 7 days (454)
Last 30 days (1680)
Last 365 days (19921)
2026 (12485)
2025 (19982)
2024 (23803)
2023 (27365)
2022 (35564)
2021 (38123)
2020 (34285)
2019 (24179)
2018 (18289)
2017 (19560)
2016 (18718)
2015 (25088)
2014 (22312)
2013 (18644)
2012 (20640)
2011 (20814)
2010 (20624)
Location
Africa (252)
Alabama (72)
Alaska (2)
Arizona (303)
Arkansas (11)
Asia (20201)
Australia (2281)
California (12052)
Canada (3169)
China (596)
Colorado (486)
Connecticut (412)
Delaware (212)
Europe (27868)
Florida (1812)
Georgia (378)
Hawaii (3)
Idaho (46)
Illinois (800)
India (49)
Indiana (335)
Iowa (14)
Japan (434)
Kansas (100)
Kentucky (31)
Louisiana (28)
Maine (30)
Maryland (1209)
Massachusetts (8077)
Michigan (308)
Minnesota (572)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (63)
New Jersey (2695)
New Mexico (13)
New York (2895)
North Carolina (1286)
North Dakota (4)
Northern California (6048)
Ohio (284)
Oklahoma (14)
Oregon (18)
Pennsylvania (2265)
Puerto Rico (23)
Rhode Island (35)
South America (428)
South Carolina (76)
South Dakota (1)
Southern California (4977)
Tennessee (124)
Texas (1926)
United States (39498)
Utah (363)
Vermont (1)
Virginia (155)
Washington D.C. (44)
Washington State (937)
West Virginia (1)
Wisconsin (75)
497,661 Results for "teva neuroscience inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy
June 11, 2026
·
5 min read
Press Releases
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
April 29, 2026
·
8 min read
Press Releases
Teva Releases Q2 2026 Aide Memoire
June 19, 2026
·
2 min read
Press Releases
Teva to Present at the Goldman Sachs Global Healthcare Conference
June 2, 2026
·
3 min read
Press Releases
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
May 21, 2026
·
7 min read
Press Releases
Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
June 4, 2026
·
5 min read
Press Releases
Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care
June 8, 2026
·
11 min read
Press Releases
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
July 9, 2026
·
6 min read
Press Releases
Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
April 30, 2026
·
5 min read
Press Releases
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
May 18, 2026
·
4 min read
1 of 49,767
Next
